Table 3 Comparison of treatment effects of pivotal trial using surrogate markers with matched postapproval trials using surrogate markers: primary and sensitivity analyses
| Â | Summary difference between standardized mean differences or relative odds ratios (95% CI) |
|---|---|
Method of analyses | |
 At least two matching criteria (n = 43) | |
  Reported non-continuous endpoints | 1.50 (1.01 to 2.23) |
  Reported continuous endpoints | 0.01 (−0.15 to 0.16) |
  All standardized as odds ratios (secondary) | 1.12 (0.88 to 1.42) |
 At least three matching criteria (n = 39) | |
  Reported non-continuous endpoints | 1.45 (0.99 to 2.14)a |
  Reported continuous endpoints | 0.05 (−0.08 to 0.19) |
  All standardized as odds ratios (secondary) | 1.17 (0.95 to 1.45) |
 All four matching criteria (n = 33) | |
  Reported non-continuous endpoints | 1.21 (0.89 to 1.64) |
  Reported continuous endpoints | 0.06 (−0.10 to 0.21) |
  All standardized as odds ratios (secondary) | 1.13 (0.90 to 1.42) |